Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Tauopathies 1Neurodegenerative Diseases 1Nervous System Diseases 1Mental Disorders 1Inflammation 1Dementia 1Cognitive Dysfunction 1Central Nervous System Diseases 1Brain Diseases 1Alzheimer Disease 1

Interventions

dolutegravir 1XENP 1595 1Trimethoprim, Sulfamethoxazole Drug Combination 1Ritonavir 1Nucleosides 1Darunavir 1Clindamycin 1Cephalexin 1Anti-Bacterial Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Inflammation × XENP 1595 × Clear all
NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡